Bioatla, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2020
March 25, 2021 at 09:00 am EDT
Share
BioAtla, Inc. reported consolidated earnings results for the year ended December 31, 2020. For the year, the company reported Collaboration revenue of $429,000 against $5,200,000 a year ago. Loss from operations was $30,099,000 against $28,268,000 a year ago. Net loss attributable to BioAtla, Inc./BioAtla LLC was $35,853,000 against $29,794,000 a year ago.
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
BIOATLA, INC. 
